文献速递妇科

PARP抑制剂对患者、支付方和财务援助项目的经济负担

The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
PubMed 文献 · Gynecol Oncol · 2021-01-04

本研究基于单中心药房数据库,分析2015年5月至2019年9月卵巢癌患者使用PARP抑制剂的费用分担模式。对41张有费用数据的处方分析232个处方月,显示每月总药物费用平均12422美元,患者自付平均46美元(中位0美元),支付方平均12019美元,财务援助项目平均358美元。

要点

  • 患者每月自付费用普遍较低,75%患者每月自付不足5美元。
  • 近半数处方使用财务援助项目,对保障药物可及性起关键作用。

核心结论

  • 患者自付费用普遍较低,但财务援助项目对确保PARP抑制剂可及性至关重要。

研究设计与样本

  • 单中心回顾性研究,利用药房数据库识别2015年5月至2019年9月开具PARP抑制剂的卵巢癌患者。

主要发现

  • 42张(45%)处方通过任何类型的财务援助项目获得。
  • 每月总药物费用平均12422美元,中位13700美元。
  • 患者每月自付费用平均46美元,中位0美元(IQR 0-4)。
  • 支付方每月费用最高,平均12019美元,中位13662美元(IQR 9914-14709)。
  • 财务援助项目每月贡献平均358美元,中位0美元(IQR 0-150)。

关键数值与推荐

  • 75%的患者每月自付费用低于5美元。
  • 有费用数据的41张处方中,18张(44%)为rucaparib,18张(44%)为niraparib,5张(12%)为olaparib。

临床怎么用

  • 临床医生应了解财务援助项目在PARP抑制剂治疗中的重要作用,并协助患者申请以降低自付费用。
  • 对于公共保险或Medicare保险患者,需关注其自付费用可能较高。

局限性

  • 样本量小且来自单一机构,结果可能不可推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Poly(ADP-ribose) polymerase (PARP) inhibitors are expensive and their use is expanding. We aimed to evaluate cost sharing patterns between patients, payors, and financial assistance programs. METHODS: We identified ovarian cancer patients prescribed a PARP inhibitor from 5/2015-9/2019 using our pharmacy database. Cost information was collected for patients who filled their prescription at our specialty pharmacy. We calculated descriptive statistics for monthly PARP inhibitor costs for patients, payors, and financial assistance programs. We used Wilcoxon rank sum tests to evaluate monthly costs based on insurance characteristics. RESULTS: Seventy-six patients filled 94 different PARP inhibitor prescriptions with 42 (45%) prescriptions obtained using any type of financial assistance program. We analyzed 232 prescription months for the 41 prescriptions with available cost data. This included 18 (44%) prescriptions for rucaparib, 18 (44%) for niraparib, and 5 (12%) for olaparib. The total monthly drug cost was average $12,422 and median $13,700. The monthly out-of-pocket (OOP) cost for patients was average $46 and median $0 (IQR $0-4). Payors had the highest monthly costs with average $12,019 and median $13,662 (IQR $9914-14,709). Financial assistance programs contributed average $358 and median $0 per month (IQR $0-150). Patients with public (p<0.01) or Medicare insurance (p<0.01) had higher OOP costs than without. CONCLUSIONS: OOP costs were generally low with 75% of patients paying <$5 per month. While limited by small sample size at a single institution, financial assistance programs appear to play a critical role to ensure access to PARP inhibitors as nearly 50% of patients utilized these programs.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Goldsberry WN, Summerlin SS, Guyton A, et al. The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost? Gynecol Oncol. 2021. PMID: 33414026. doi:10.1016/j.ygyno.2020.12.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。